Premium
Ki67 and cyclin A as prognostic factors in early breast cancer. What are the optimal cut‐off values?
Author(s) -
Ahlin C,
Aaltonen K,
Amini RM,
Nevanlinna H,
Fjällskog ML,
Blomqvist C
Publication year - 2007
Publication title -
histopathology
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.626
H-Index - 124
eISSN - 1365-2559
pISSN - 0309-0167
DOI - 10.1111/j.1365-2559.2007.02798.x
Subject(s) - breast cancer , immunohistochemistry , tissue microarray , cyclin d1 , cyclin , cancer , chemotherapy , decile , medicine , adjuvant therapy , adjuvant chemotherapy , oncology , cell cycle , mathematics , statistics
Aims: To find the optimal cut‐off values for cyclin A and Ki67 in early breast cancer tumours and to evaluate their prognostic values. Methods and results: Tissue microarray (TMA) slides were constructed from 570 T1–4 N0–1 M0 breast cancer tumours. The TMA slides were stained for cyclin A and Ki67 using immunohistochemistry with commercial antibodies. To investigate the optimal cut‐off values for cyclin A, Ki67 average and maximum values the material was split into two parts at cut‐offs defined by dividing it into deciles. For each cut‐off value the relative risk (RR) for metastasis‐free survival (MFS) and overall survival (OS) was calculated comparing patients with high versus low cyclin A or Ki67 expression. When using a cut‐off value around the seventh decile, cyclin A and Ki67 score correlated with the highest RR ratio for MFS in the chemotherapy‐naïve subgroup. Among patients having received adjuvant chemotherapy, no statistically significant differences in MFS or OS were found. Conclusions: The optimal cut‐off value for cyclin A average is 8% and for cyclin A maximum value 11%; for Ki67 the corresponding values are 15% and 22%. Additional studies are needed to verify these results.